Intrinsic Value of S&P & Nasdaq Contact Us

Surrozen, Inc. SRZN NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
48/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$40.00
+28.7%

Surrozen, Inc. (SRZN) — Analyst outlook / Analyst consensus target is. Based on 6 analyst ratings, the consensus is bullish — 4 Buy, 2 Sell.

The consensus price target is $40.00, representing an upside of 28.7% from the current price $31.07.

Analysts estimate Earnings Per Share (EPS) of $-14.94 and revenue of $0.01B for the next fiscal year.

Earnings Per Share (EPS) track record: 2024: actual $-21.67 vs est $-14.94 (missed -45%). 2025: actual $-32.37 vs est $-8.76 (missed -269.4%). Analyst accuracy: 48%.

SRZN Stock — 12-Month Price Forecast

$40.00
▲ +28.74% Upside
Average Price Target
Based on 6 Wall Street analysts offering 12-month price targets for Surrozen, Inc., the price target is $40.00.
The average price target represents a +28.74% change from the last price of $31.07.

SRZN Analyst Ratings

Buy
6
Ratings
4 Buy
2 Sell
Based on 6 analysts giving stock ratings to Surrozen, Inc. in the past 3 months
Rating breakdown
Buy
4 67%
Sell
2 33%
67%
Buy
4 analysts
0%
Hold
0 analysts
33%
Sell
2 analysts

EPS Estimates — SRZN

48%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024 Actual –$21.67 vs Est –$14.94 ▼ 31.1% off
2025 Actual –$32.37 vs Est –$8.76 ▼ 72.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.

Revenue Estimates — SRZN

80%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024 Actual $0.011B vs Est $0.010B ▲ 6.1% off
2025 Actual $0.003B vs Est $0.002B ▲ 34.0% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message